maintain fve alzheim forecast despit
confus analysi trial
page full analyst note oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
multipl sclerosi cancer novel neurology-focus
extend oncolog
strategi root merger ms
drug avonex idec cancer drug rituxan rituxan market
penetr alreadi high patent unit state
deriv profit share roch expir howev
think subcutan rituxan well novel antibodi gazyva
allow
revenu avonex
longer-act plegridi gener billion annual sale
remain lead ms interferon franchis acquir full
right ms antibodi tysabri billion annual sale
partner diagnost test isol patient lowest
progress multifoc leukoencephalopathi risk allow
patient expos jc viru
benefit tysabri strong efficaci profil low pml risk
said older product like avonex could see price power
demand erod gener version teva copaxon
launch novel high-efficaci drug reach market
base oral ms drug tecfidera strong launch solid safeti
efficaci data well potenti licens
alkerm improv gi toler expect oral ms
franchis see steadi sale around billion think tecfidera
price power demand remain rel steadi despit
oral gener class patent could
extend protect also see
signific royalti novel high-efficaci drug ocrevu approv
 europ help off-set
pressur ms franchis
outsid ms strong human genet valid
neurolog pipelin creat potenti off-set ms pressur spinal
muscular atrophi drug spinraza launch could reach
billion peak sale addit earli data alzheim drug
aducanumab could allow multi-billion-dollar
potenti approv begin
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
idec merg combin forc market
multipl sclerosi drug avonex idec cancer drug rituxan today
rituxan next-gener antibodi gazyva market via
collabor roch market novel ms drug tysabri
tecfidera independ hemophilia therapi eloct alprolix
partner sobi spun part bioverativ biogen
sever drug candid phase trial neurolog
neurodegen diseas launch spinraza partner ioni
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
maintain fve alzheim forecast
despit confus analysi trial oct
eisai present key subset analysi phase studi
eisai amyloid antibodi oct
clinic trial alzheim diseas ctad
meet barcelona make chang
alzheim sale estim
fair valu estim time still assum
billion amyloid antibodi sale amyloid
antibodi approv use probabl
approv drug even remov amyloid
antibodi valuat arriv fair valu
estim near recent trade level addit
valuat factor virtual long-term success
includ tau program think unrealist
still see steadi neurolog focu increasingli
divers portfolio pipelin support wide moat
eisai still discuss idea phase
program regul
uncertainti futur program aducanumab
phase studi fulli enrol final data expect
earli overal think data support conclus
drug target aggreg form amyloid
reduc plaqu burden slow clinic declin high
dose although inconsist subset data
enough prevent us rais assum
probabl approv
updat carrier subset data high-dos
arm versu placebo appear refut idea
imbal carrier high dose arm
placebo arm drove initi posit result juli
reassur gave us confid
efficaci discuss juli note
phase studi strong overal efficaci
data highest dose signific slow
declin measur adcom slower declin
adas-cog slower declin versu placebo trend
benefit cdr-sb slower declin importantli
subset analysi show among placebo patient
carrier non-carri saw declin adcom
composit clinic endpoint use trial
similar one anoth previous discuss
imbal among genet variant
highest dose arm patient carrier
placebo arm patient carrier caus
confus debat surround interpret
howev reassur turn back confus
carrier subset clinic endpoint data suggest
carrier could actual respond better treatment
noncarri would puzzl carrier statu
factor clinic respons aducanumab
patient non-carri group appear slightli
wors placebo cdr-sb chosen primari
endpoint phase studi aducanumab
think small sampl size analysi partli
due high discontinu rate regulatori action
remov carrier high-dos arm studi
precautionari measur gener variabl
larg base
questionnair make difficult conclud
carrier respond better treatment inclin put
relianc similar reduct plaqu level
much object quantit measur carrier
noncarri high-dos arm
rais fair valu estim per
share factor recent share repurchas
increas long-term estim biosimilar-rel
alzheim s-relat revenu forecast biogen
includ billion revenu aducanumab
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sale assum probabl approv
opicinumab sale billion year
forecast approv
see oper margin
declin low potenti alzheim market
cost profit-shar eisai neurimmun
spinraza profit-shar partner ioni potenti
royalti payment counter ocrevu
royalti overal think top-lin growth
averag share-repurchas activ
enabl firm achiev averag earn per
share growth period
still rate systemat risk surround share
averag use cost equiti
assumpt align capit cost assumpt
return equiti investor like demand
assign biogen medium uncertainti rate demand
rel
inelast portfolio ms
treatment revenu remain focus one therapeut
area increasingli small number product
tecfidera spinraza base-cas scenario
expect sale flatten around billion
also assum tysabri sale peak billion
think new patient add patient test
seroneg jc viru antibodi price
power may abl counter impact
discontinu seroposit patient new
altern regimen ocrevu long run overal
rel steadi high long run
scenario think oper margin remain
bull-cas scenario -- valu per
anti-tau assum
probabl approv aducanumab
probabl aducanumab sale partli
off-set aducanumab profit share eisai royalti
neurimmun also assum book half
spinraza nusinersen still think sale could peak
near billion assum sale begin declin rather
plateau new patient treat spinraza
patient could opt either compet gene therapi
novartis/avexi small-molecul therapi roche/ptc
expect remain around billion
annual long run sale remain rel flat
despit competit think combin global sale
avonex plegridi continu fall
high-single-digit declin annual new
competit expect tysabri declin billion
billion end forecast
jcv-posit patient switch effect therapi
like ocrevu includ ocrevu sale hit billion
assum see roughli global
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
explicit forecast period also assum
tecfidera becom domin player
ms market allow secur billion annual
sale translat ms patient share
low bear-cas scenario valu
per share assum heavi discontinu new
competit threat weigh tysabri sale global
tysabri sale declin million also
forecast declin tecfidera sale beyond
bear-cas scenario factor strong competit
novel oral drug slower uptak tecfidera
follow approv cheaper gener version
copaxon scenario result global ms
market share declin low long run
achiev strong profit success
three market product field oncolog
neuroimmunolog introduct tecfidera secur
firm domin share ms market think
barrier entri high potenti biosimilar
product strong strategi
maintain leadership ms price power
strong patient need novel therapi high
pipelin particularli product factor
contribut firm wide moat return invest
capit think averag
explicit forecast period easili exceed
estim cost capit
rituxan remain standard care sever form
hematolog cancer collabor revenu receiv
partner roch boost margin
avonex lead interferon therapi ms
long-term safeti record rel conveni
tysabri achiev blockbust sale base outstand
efficaci despit rare seriou side effect think
effort target drug patient least like
experi side effect allow firm see continu
sale despit novel product cleaner safeti profil
expect combin sale tecfidera
remain around billion annual long run base
conveni oral administr rel strong efficaci
safeti profil
except tecfidera current
blockbust biolog biosimilar competit
loom threat think signific manufactur
develop cost biosimilar maker expect
incur would slow eros sale product
limit number contend abil
compet price data qualiti may also issu
biosimilar first applic avonex biosimilar
reject base insuffici efficaci delay
discontinu rituxan biosimilar push
european launch tysabri like
lower-prior target biosimilar entrant given risk
monitor potenti seriou side effect certain
see moat trend stabl think
introduct new product firm grow
late-stag pipelin off-set new competit
competit price pressur ms oncolog
increas think strong efficaci oral ms therapi
biogen tecfidera novarti gilenya inject
therapi roch launch ocrevu make
less like new patient start older inject
avonex tysabri addit payer
leverag price negoti assum
abl take avonex price increas
roughli annual net basi past sever
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
spinraza launch annual price
lack treatment option rare deadli diseas
could creat billion market
broadest exposur alzheim larg drug firm
two lead beta-amyloid antibodi eisai
neurimmun bace inhibitor eisai three tau drug
initi data aducanumab -- phase trial --
impress enough could clinic signific
replic phase think aria- edema side
effect manag addit phase data
efficaci highest dose assign probabl
approv
aducanumab
probability-weight sale billion
overal think biogen alzheim drug could see
billion sale recogn
half econom amyloid bace program
year think futur price chang
like closer mid-single-digit increas biogen
recent launch conveni interferon therapi
plegridi littl chang trend opinion
model high-single-digit declin combin
avonex/plegridi tysabri go forward addit
report revenu cancer therapi rituxan
matur patent expir draw
howev think pipelin off-set
pressur older drug roch receiv food drug
administr approv novel effect antibodi
therapi ocrevu relaps ms
compet primari progress ms
approv treatment littl off-label use
current drug add competit
landscap also benefit due roughli
royalti sale two third global
billion ms market exposur new ppm
indic biogen anti-lingo drug candid key part
ms pipelin drug could help repair myelin
sheath coat neuron give novel mechan
action potenti allow patient regain lost
function drug fail hit key endpoint
phase studi saw encourag data
clinic respons opicinumab continu move forward
develop oncolog expect partner
subcutan rituxan also next-gener drug
gazyva launch leukemia product
superior efficaci profil rituxan recent
approv larg indol first-lin lymphoma set
extend oncolog profit stream
individu odd approv mix bullish
novel broader neurolog rare-diseas
pipelin includ sever product high risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lead billion global ms market
avonex tysabri launch tecfidera
secur firm domin least next
oavonex lost edg lead ms drug
similar competitor nip heel novel oral
therapi launch gener copaxon could
trigger discount
otecfidera remain strong option first-lin ms
patient deal give right
could improv tecfidera gi side
otysabri efficaci still counter pml risk
particularli patient test posit jc
viru antibodi may opt switch potenti
neurolog pipelin outsid ms includ
spinraza sever alzheim therapi
help diversifi revenu boost sale growth
drive growth oral
competit roche/ptc gene therapi avexi
could threaten franchis
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end cash balanc billion free
cash flow around billion annual help fund futur
repurchas allow firm flexibl size
futur acquisit firm cash invest
balanc sheet match similar amount debt
matur issu billion
debt help fund share-repurchas program
histor focus return excess cash
sharehold via buyback limit acquisit
collabor record strong expect tuck-in
acquisit go forward billion free cash
flow gener spent vast
major cash repurchas averag
repurchas price per share
profit depend four key blockbust
high-risk potenti high-reward pipelin
physician payer fail support gazyva use
rituxan despit strong superior data leukemia
larg lymphoma set roch could
vulner competit cheaper biosimilar rituxan
begin earli revenu
roch collabor feed directli bottom line
boost margin plegridi like help
maintain lead interferon market expect
gener copaxon weigh sale inject ms
therapi ms portfolio enjoy tremend
price power unit state insur could begin
find way put pressur futur price increas
competitor reach market avonex plegridi
exclud nation formulari
tecfidera sale see slower growth partli due
concern case pml gastrointestin issu
oral drug celgen ozanimod pois
enter market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
ft growth trea
fidel manag research compani
share
fund
share
fund
scango took ceo juli longtim
execut jame mullen serv ceo
development-stag biotech year
previous spend year bayer scango help
refocu pipelin neurodegen diseas
neurology-rel indic build strong team
neurolog drug discoveri emphas small tuck-in
commerci offic toni kingsley chief doug
left scango depart
begin decis spin firm
hemophilia franchis led specul firm
sale despit turnov chief medic offic alfr
sandrock decad experi support
pipelin new ceo michael vounatso previous
chief commerci offic career
longtim director william young step
role independ chairman replac stelio
papadopoulo chairman regulu
annual meet may overal see
board well qualifi divers independ despit
long tenur sever director applaud
effort emphas restrict stock option
compens packag top execut
believ align interest sharehold howev
take-over defens author prefer stock may
work interest sharehold complex right
agreement partner roch
trigger acquir could damp
enthusiasm potenti acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
solid third quarter top-lin growth
bottom-lin growth driven multipl sclerosi
franchis stabil growth spinal muscular atrophi
therapi spinraza maintain fair valu
estim subset analysi phase studi eisai
amyloid antibodi present
oct clinic trial alzheim diseas
meet barcelona expect result continu
support safeti efficaci howev
updat data reveal imbal carrier
high-dos arm placebo arm drove
initi posit result juli would expect lower
estim aducanumab histor data vari
significantli among amyloid antibodi base
design two drug differ target bind
still assum billion amyloid antibodi sale
amyloid antibodi approv use
probabl approv drug even remov
amyloid antibodi valuat arriv
fair valu estim near recent trade level
addit valuat factor virtual long-
term success remain early-stag alzheim
pipelin includ tau program think
unrealist beyond oct expect sever key catalyst
culmin final analysi aducanumab
phase alzheim program earli remov
pain drug model follow sciatica trial
failur model includ sale lupu ucb
collabor also recent midstag trial failur
also includ ioni second al program
model remain bullish genet driven
drug develop neurodegen diseas still
see steadi neurolog focu increasingli
divers portfolio pipelin support wide moat
discuss juli note phase studi
strong efficaci data highest dose
signific slow declin measur adcom
slower declin adas-cog slower declin
versu placebo trend benefit cdr-sb
slower declin analysi present oct
includ subgroup analysi clarifi whether
strong efficaci driven imbal among
genet variant highest-dos arm
patient placebo arm patient
clear evid show differ rate declin
patient although
patient tend get diseas
younger age also like experi aria-
 brain swell encourag direct
posit data second-highest dose group
even higher proport patient
placebo group yet still saw posit trend
aducanumab phase data expect earli
stand largest catalyst sever smaller
data readout drive firm time
overal expect pipelin remain
alzheim data earli phase tau antibodi
psp data phase antisens therapi
al data head-to-head data
tecfidera data launch data
ophthalmolog gene therapi earli
turn ms sma therapi continu
assum lower-than-consensu revenu long term
due larg competit ms tecfidera tysabri
sale stabil third quarter long run
expect
annual driven competit patient oral
declin price power factor approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
late help see higher
retent rate new fumar patient also potenti
oral competit celgen ozanimod
johnson johnson ponesimod merck
kgaa mavenclad sma drug spinraza
continu grow strongli particularli outsid
assum sale flatten begin declin
novarti gene therapi launch roch
oral therapi risdiplam could launch
eisai detail spark confus
maintain thesi fve jul
alzheim associ intern confer
juli eisai present detail data
phase studi amyloid antibodi support
view drug potenti treat patient
earliest stage diseas make
chang fair valu estim
share fell hour investor process detail
think continu support strong efficaci
safeti profil drug howev due patient
imbal key arm studi option earli
file regul like tabl
includ valuat futur subgroup analysi
clarifi efficaci profil therapi think data
support amyloid theori potenti
similar product aducanumab
recent complet phase enrol
data earli factor billion amyloid
antibodi sale aducanumab
approv use probabl approv
drug still see steadi neurolog focu
increasingli divers portfolio pipelin support
dive deeper data patient highest-
dose arm saw impress reduct amyloid burden
evidenc pet imag convert
amyloid posit neg patient arm saw
signific slow declin measur adcom
slower declin adas-cog slower declin
versu placebo trend benefit cdr-sb
slower declin measur declin vari
level emphasi cognit function like
explain variat result howev size
aducanumab phase trial patient give
firm power demonstr signific cdr-
sb primari endpoint aducanumab trial
worst-cas scenario unplan imbal
patient carri genet variant may
driven efficaci drug rel placebo
still think unlik scenario continu model
probabl drug eventu approv
intern regul request chang trial
result patient
alloc second-highest-dos arm mg/kg
monthli rather highest-dos arm mg/kg
patient
compris placebo arm
high-dos arm clear evid show
differ rate declin
patient although patient
tend get diseas younger age
also like experi aria- brain
swell encourag direct posit
data second-highest dose group even
higher proport patient
placebo group yet still saw posit trend clinic
background amyloid hypothesi
drug develop alzheim see healthcar
observ wide-moat firm alzheim diseas
market mispric opportun
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
includ head-to-head data ms drug
phase data al drug alzheim drug
tau antibodi phase data sciatica
phase data ophthalmolog gene therapi
still signific risk surround
alzheim program fail achiev
signific result month earlier year howev
earlier month firm announc month
highest mg /kg biweekli dose show
statist signific abil slow clinic declin
base alzheim diseas composit score rel
placebo look sole dosag benefit
seen earli six month treatment brain
imag indic reduct brain amyloid fit
drug expect mechan action
background amyloid hypothesi drug
develop alzheim see healthcar observ
wide-moat firm alzheim diseas market
mispric opportun
slightli rais fve strong result
ahead detail jul
slightli increas fair valu estim
per share follow strong second-quart
result updat model billion share
repurchas averag repurchas price around
per share repres good valu rel
view firm intrins valu well stronger long-
term revenu tie manufactur sale
firm biosimilar via collabor samsung
biolog demand ms drug appear steadi
spinraza continu see solid revenu strong
growth exclud firm steadili
expand mid-stag pipelin product pfizer
stroke alivegen
neuromuscular diseas program remain earli
signific impact valuat contrast
alzheim portfolio increasingli
import impact valuat tomorrow present
detail phase data amyloid antibodi
shed light drug efficaci alzheim
diseas higher dose also reflect
potenti similar product aducanumab
recent complet phase enrol
data earli factor billion amyloid
antibodi sale aducanumab
approv use probabl approv
drug strong data could push us increas fair
valu estim much particularli
strong enough potenti earli regulatori file
data edg statist signific could lead us
decreas fair valu estim much
continu see steadi neurolog focu
increasingli divers portfolio pipelin support
beyond aducanumab pois see
signific uptick data readout next year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
